Alunbrig 180 mg

Alunbrig 180 mg tablets contain brigatinib, a medication used for targeted therapy. This oral treatment is designed for specific medical conditions and is manufactured by Takeda Canada Inc.

Alunbrig 180 mg tablets are primarily used in targeted therapy for certain types of cancer. Brigatinib, the active ingredient, is often prescribed for conditions where specific proteins are involved. Patients may wonder, 'What is brigatinib used for?' and the answer typically involves its role in managing advanced or metastatic cancers.

Common effects of Alunbrig 180 mg tablets may include nausea, fatigue, and cough. Some users might experience changes in taste or shortness of breath. These effects can vary from person to person and are not exhaustive.

Alunbrig 180 mg tablets should be handled with care, following the guidance of a healthcare provider. It is important to store the medication properly and to be aware of potential side effects. Always consult a healthcare professional before starting any new medication.

Alunbrig 180 mg tablets may interact with certain medications, including those that affect liver enzymes. It is advisable to discuss all current medications with a healthcare provider to avoid potential interactions. Alcohol and other substances may also affect the efficacy of brigatinib.